MODERN CLASSIFICATION AND MODERN VIEWS OF RATIONAL HEMOSTATIC PHARMACOTHERAPY

Аннотация

This article presents an extensive overview of current approaches to the classification of hemostatic agents and evaluates modern concepts of rational hemostatic pharmacotherapy. It analyzes the mechanisms of action, clinical benefits, and limitations of various groups of hemostatic drugs, considering recent evidence-based guidelines. Special emphasis is placed on individualized therapy, pharmacodynamic characteristics, and safety issues in different clinical situations where bleeding control is required. This study provides an in-depth scientific evaluation of contemporary principles governing the use of hemostatic pharmacotherapy. It focuses on advanced drug groups, their functional distinctions, and current clinical directions for managing various bleeding states. Special attention is given to mechanistic diversity, therapeutic precision, and safety-centered decision-making. Modern diagnostic technologies and personalized strategies are also assessed for their contribution to optimizing treatment effects, reducing adverse complications, and improving outcomes. Keywords: hemostatic agents, classification, bleeding, coagulation, antifibrinolytics, pharmacotherapy, evidence-based medicine. Introduction: Hemostasis is a complex physiological process responsible for maintaining vascular integrity and preventing excessive blood loss. Disorders of hemostasis may lead to clinical conditions such as hemorrhage, surgical bleeding, trauma-related blood loss, and coagulation abnormalities. The development of hemostatic pharmacotherapy has evolved significantly in recent years, with advancements in understanding coagulation pathways, platelet activity, and fibrinolytic mechanisms. Modern perspectives emphasize precise drug selection based on the etiology of bleeding, patient-specific factors, and pharmacological characteristics of each agent. Current classifications incorporate both traditional and newly introduced hemostatic agents that target different stages of coagulation, platelet aggregation, and fibrinolysis, ensuring a rational and individualized therapeutic approach. Control of hemorrhagic conditions requires a comprehensive understanding of biological mechanisms responsible for achieving vascular stabilization. Recent progress in pharmacological science has enriched treatment options aimed at enhancing coagulation potential, reinforcing platelet activity, and suppressing premature fibrin degradation. As surgical procedures, trauma incidents, and coagulation disorders continue to rise, updated knowledge of drug categories and their applications has become critical. Current research highlights that therapeutic decisions must be based on clinical context, patient characteristics, and mechanistic targeting. Integrating laboratory monitoring with drug-specific properties ensures accuracy in choosing the most effective intervention. 188 Noyabr, 2025-Yil Materials and Methods: The research is based on a comprehensive review of recent scientific literature, clinical guidelines, randomized controlled trials, and meta-analyses related to hemostatic pharmacotherapy. Analytical methods included structural classification of drugs, comparative evaluation of their mechanisms of action, and assessment of clinical efficacy in various bleeding conditions. Sources were selected from international pharmacology databases, focusing on studies published within the last ten years to ensure contemporary relevance. The methodology included thematic categorization of hemostatic drug classes, evaluation of pharmacodynamic and pharmacokinetic properties, and synthesis of evidence on clinical outcomes and safety profiles. Results: The modern classification of hemostatic drugs identifies several major categories. The first group comprises agents that enhance coagulation factor activity, including vitamin K preparations, fibrinogen concentrates, prothrombin complex concentrates, and recombinant clotting factors. The second group includes antifibrinolytic drugs such as tranexamic acid and aminocaproic acid, which stabilize formed clots by inhibiting plasmin activation. The third group consists of local hemostatic agents including collagen sponges, oxidized cellulose, fibrin sealants, and thrombin-based products that achieve rapid bleeding control during surgical interventions. The fourth group encompasses drugs that improve platelet function, such as desmopressin and specific platelet-stimulating agents used in thrombocytopenic states. The fifth group represents novel targeted hemostatic molecules that modulate specific steps in coagulation cascades and have shown promising clinical benefits. Evidence shows that timely and rational selection of these drugs reduces transfusion requirements, improves surgical outcomes, and enhances patient safety. Findings demonstrate that therapeutic efficiency depends largely on the precise selection of drug categories aligned with the underlying pathophysiological pattern. Concentrates supplying deficient